Invention Grant
- Patent Title: Oxybutynin transdermal therapeutic system muscarinic agonist combination
-
Application No.: US15556206Application Date: 2016-03-04
-
Publication No.: US10596139B2Publication Date: 2020-03-24
- Inventor: Thomas N. Chase , Kathleen E. Clarence-Smith
- Applicant: CHASE PHARMACEUTICALS CORPORATION
- Applicant Address: US NJ Parsippany
- Assignee: Chase Pharmaceuticals Corporation
- Current Assignee: Chase Pharmaceuticals Corporation
- Current Assignee Address: US NJ Parsippany
- Agent Roy Issac
- International Application: PCT/US2016/020815 WO 20160304
- International Announcement: WO2016/144719 WO 20160915
- Main IPC: A61K31/216
- IPC: A61K31/216 ; A61K45/06 ; A61K31/439 ; A61K31/4439 ; A61K9/70

Abstract:
Pharmaceutical compositions and combinations containing a muscarinic receptor antagonist, such as oxybutynin in a transdermal therapeutic system, and a muscarinic receptor agonist, optionally with an acetyl cholinesterase inhibitor, and methods of using the same for treatment of hypocholinergic disorders of the central nervous system such as Alzheimer type dementia. The respective pharmaceutical compositions and combinations of the present invention allow for safe administration of high doses of muscarinic receptor agonist, and improved efficacy of the muscarinic receptor agonist for treatment of hypocholinergic disorders of the central nervous system. The pharmaceutical compositions and combinations also allow for a maximum supply of acetylcholine to the central nervous system, when an acetyl cholinesterase inhibitor is used in combination with a muscarinic receptor antagonist and a muscarinic receptor agonist.
Public/Granted literature
- US20180050008A1 OXYBUTYNIN TRANSDERMAL THERAPEUTIC SYSTEM MUSCARINIC AGONIST COMBINATION Public/Granted day:2018-02-22
Information query